BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 28466157)

  • 21. [Circulating Tumor DNA (ctDNA) Detection Using BEAMing and Its Clinical Significance.].
    Nakamura K
    Rinsho Byori; 2016 May; 64(4):400-406. PubMed ID: 29182806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating Tumor DNA: A Step into the Future of Cancer Management.
    Fernandes Marques J; Pereira Reis J; Fernandes G; Hespanhol V; Machado JC; Costa JL
    Acta Cytol; 2019; 63(6):456-465. PubMed ID: 30852572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
    Fiala C; Diamandis EP
    Clin Chem Lab Med; 2020 Sep; 58(10):1651-1653. PubMed ID: 32160156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current situation and prospect of breast cancer liquid biopsy].
    Zhou B; Xin L; Xu L; Ye JM; Liu YH
    Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):106-109. PubMed ID: 29397622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How liquid biopsies can change clinical practice in oncology.
    Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
    Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective.
    Postel M; Roosen A; Laurent-Puig P; Taly V; Wang-Renault SF
    Expert Rev Mol Diagn; 2018 Jan; 18(1):7-17. PubMed ID: 29115895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent Advances in Liquid Biopsy in Precision Oncology Research.
    Sato Y; Matoba R; Kato K
    Biol Pharm Bull; 2019; 42(3):337-342. PubMed ID: 30828064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Introduction and Clinical Application of Cell-Free Tumor DNA.
    Li J; Liu R; Huang C; Chen S; Xu M
    Methods Mol Biol; 2018; 1754():45-65. PubMed ID: 29536437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
    Croessmann S; Park BH
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in liquid biopsy using circulating tumor cells and circulating cell-free tumor DNA for detection and monitoring of breast cancer.
    Zhang X; Ju S; Wang X; Cong H
    Clin Exp Med; 2019 Aug; 19(3):271-279. PubMed ID: 31190187
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Tumor DNA (ctDNA) and Its Role in Gynecologic Malignancies.
    Pomerantz T; Brooks R
    Curr Treat Options Oncol; 2024 Apr; 25(4):510-522. PubMed ID: 38472567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liquid Biopsy and Lung Cancer.
    Pisapia P; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating cell-free tumor DNA analysis in pediatric cancers.
    Andersson D; Fagman H; Dalin MG; Ståhlberg A
    Mol Aspects Med; 2020 Apr; 72():100819. PubMed ID: 31563277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liquid biopsy in lymphoma: Molecular methods and clinical applications.
    Cirillo M; Craig AFM; Borchmann S; Kurtz DM
    Cancer Treat Rev; 2020 Dec; 91():102106. PubMed ID: 33049623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of incipient tumours by screening of circulating plasma DNA: hype or hope?
    Lenaerts L; Tuveri S; Jatsenko T; Amant F; Vermeesch JR
    Acta Clin Belg; 2020 Feb; 75(1):9-18. PubMed ID: 31578135
    [No Abstract]   [Full Text] [Related]  

  • 39. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.
    Jiang N; Pan J; Fang S; Zhou C; Han Y; Chen J; Meng X; Jin X; Gong Z
    Clin Chim Acta; 2019 Aug; 495():331-337. PubMed ID: 31054913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.